Scotts Miracle-Gro (NYSE: SMG) director discloses 18 dividend equivalent rights
Rhea-AI Filing Summary
Scotts Miracle-Gro Company director files Form 4 for derivative award. A company director reported acquiring 18 dividend equivalent rights on December 5, 2025, tied to existing deferred stock unit (DSU) or restricted stock unit (RSU) grants. These rights become exercisable in step with the related DSUs or RSUs and each right is the economic equivalent of one common share of Scotts Miracle-Gro. Following this transaction, the director beneficially owned 33 derivative securities in direct ownership form.
Positive
- None.
Negative
- None.
FAQ
What did Scotts Miracle-Gro (SMG) disclose in this Form 4 filing?
The filing shows a director of Scotts Miracle-Gro Company acquired 18 dividend equivalent rights on December 5, 2025, related to existing DSU or RSU grants.
Who is the reporting person in the Scotts Miracle-Gro (SMG) Form 4 and what is their role?
The reporting person is a director of Scotts Miracle-Gro Company, as indicated by the checked box for the director relationship on the form.
What are the dividend equivalent rights reported by the Scotts Miracle-Gro (SMG) director?
The filing explains that dividend equivalent rights accrue on DSU or RSU grants, become exercisable proportionately with those DSUs or RSUs, and each is the economic equivalent of one common share of Scotts Miracle-Gro.
How many derivative securities does the Scotts Miracle-Gro (SMG) director own after this transaction?
After acquiring 18 dividend equivalent rights, the director beneficially owned 33 derivative securities, held in direct ownership form.
Does this Scotts Miracle-Gro (SMG) Form 4 involve non-derivative common shares?
The provided excerpt only shows activity in Table II for derivative securities (dividend equivalent rights) and does not list any non-derivative common share transactions in Table I.
When did the earliest reported transaction in this Scotts Miracle-Gro (SMG) Form 4 occur?
The earliest reported transaction date in the filing is December 5, 2025, which is also the transaction date for the dividend equivalent rights.